Healthcare

• Imagion Biosystems shares rose9.09%toAUD 0.012.• The company recorded turnover of approximatelyAUD 500during the session.• Imagion Biosystems has a market capitalisation of approximatelyAUD 6.48 million.• The stock remains14.29% lower over the past year, despite the latest rally.

Ryman Healthcare Ltd (ASX:RYM) shares traded 0.28% higher at AUD 1.78 during the afternoon session on 14 July 2026 after the company released its trading update for the quarter ended 30 June 2026. Despite the modest daily increase, the stock remained down 21.71% over …

Orthocell Limited (ASX:OCC) has outlined its next commercial growth phase after reporting record annual and quarterly revenue, wider adoption of its Remplir nerve repair product and continued expansion across the United States. The company’s Q4 FY26 investor presentation showed that U.S. commercialisation remained ahead …

• Neurotech International shares surged12.50%toAUD 0.018.• The company has a market capitalisation of approximatelyAUD 23.72 million.• The stock is broadly unchanged over the past year, with a0% one-year return.• Investors continue monitoring clinical trial progress and regulatory developments across the company's therapeutic programs.

For a company with a clinically validated diagnostic test — PromarkerD has been validated to predict which patients with type 2 diabetes will develop kidney disease within four years, a clinically meaningful advance in diabetic nephropathy management — the scale of the share price …

For a clinical-stage biotech company with a market capitalisation of under $8 million, a 15% single-session fall is a significant event that in most cases reflects either a specific clinical or regulatory development, or the combination of thin trading liquidity and the binary nature …

• BLS Pharmaceuticals shares rose7.78%toAUD 0.97.• The company has a market capitalisation of approximatelyAUD 223.08 million.• The stock has gained125.58% over the past year, making it one of the stronger-performing healthcare stocks on the ASX.• Investors continue monitoring product development activities, commercial progress and …